Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (12683)
All Articles published online
|
Publishing Process of This Article
|
Nov 21, 2015 (publication date) through Nov 29, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i43/12322.htm |
| Number | Citing Articles |
| 1 |
Ayfer Beyaz Coşkun, Adviye Gülçin Sağdiçoğlu Celep. Therapeutic modulation methods of gut microbiota and gut-liver axis. Critical Reviews in Food Science and Nutrition 2022; 62(23): 6505 doi: 10.1080/10408398.2021.1902263
|
| 2 |
Vincenzo B. Polsinelli, Lara Marteau, Sanjiv J. Shah. The role of splanchnic congestion and the intestinal microenvironment in the pathogenesis of advanced heart failure. Current Opinion in Supportive & Palliative Care 2019; 13(1): 24 doi: 10.1097/SPC.0000000000000414
|
| 3 |
Xin Zeng, Xia Sheng, Pei-Qin Wang, Hai-Guang Xin, Yi-Bin Guo, Yong Lin, Jia-Wei Zhong, Cheng-Zhi He, Jie Yin, Tao-Tao Liu, Wei-Juan Ma, Xiao Xiao, Pei-Mei Shi, Zong-Li Yuan, Ling Yang, Xiong Ma, Jian-Ming Xu, Xi-Zhong Shen, Chang-Qing Yang, Xuan Zhu, Nong-Hua Lv, Wei-Fen Xie. Low-dose rifaximin prevents complications and improves survival in patients with decompensated liver cirrhosis. Hepatology International 2021; 15(1): 155 doi: 10.1007/s12072-020-10117-y
|
| 4 |
Kensuke Kitsugi, Kazuhito Kawata, Hidenao Noritake, Takeshi Chida, Kazuyoshi Ohta, Jun Ito, Shingo Takatori, Maho Yamashita, Tomohiko Hanaoka, Masahiro Umemura, Moe Matsumoto, Takafumi Suda. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation. Journal of Clinical Medicine 2023; 12(6): 2210 doi: 10.3390/jcm12062210
|
| 5 |
Huw Purssell, Peter J Whorwell, Varinder S Athwal, Dipesh H Vasant. Non-alcoholic fatty liver disease in irritable bowel syndrome: More than a coincidence?. World Journal of Hepatology 2021; 13(12): 1816-1827 doi: 10.4254/wjh.v13.i12.1816
|
| 6 |
Tomasz Banasiewicz, Waldemar Machała, Maciej Borejsza Wysocki, Maciej Lesiak, Sebastian Krych, Małgorzata Lange, Piotr Hogendorf, Adam Durczyński, Jarosław Cwaliński, Tomasz Bartkowiak, Adam Dziki, Wojciech Kielan, Stanisław Kłęk, Łukasz Krokowicz, Krzysztof Kusza, Piotr Myśliwiec, Michał Pędziwiatr, Piotr Richter, Jacek Sobocki, Marek Szczepkowski, Wiesław Tarnowski, Wojciech Zegarski, Michał Zembala, Krzysztof Zieniewicz, Grzegorz Wallner. Principles of minimize bleeding and the transfusion of blood and its components in operated patients – surgical aspects. Polish Journal of Surgery 2023; 95(5): 14 doi: 10.5604/01.3001.0053.8966
|
| 7 |
K. S. Gala, E. Winrich, S. K. Jha, R. Parthasarathy, V. Vatsalya. Alcohol Use Disorder and the Gut Microbiome. Current Addiction Reports 2023; 11(1): 105 doi: 10.1007/s40429-023-00527-x
|
| 8 |
Jasmohan S. Bajaj, Giovanni Barbara, Herbert L. DuPont, F. Mearin, Antonio Gasbarrini, Jan Tack. New concepts on intestinal microbiota and the role of the non-absorbable antibiotics with special reference to rifaximin in digestive diseases. Digestive and Liver Disease 2018; 50(8): 741 doi: 10.1016/j.dld.2018.04.020
|
| 9 |
Vincenzo B. Polsinelli, Arjun Sinha, Sanjiv J. Shah. Visceral Congestion in Heart Failure: Right Ventricular Dysfunction, Splanchnic Hemodynamics, and the Intestinal Microenvironment. Current Heart Failure Reports 2017; 14(6): 519 doi: 10.1007/s11897-017-0370-8
|
| 10 |
Caio Pupin Rosa, Gustavo Andrade Brancaglion, Tatimara M. Miyauchi-Tavares, Patrícia Paiva Corsetti, Leonardo Augusto de Almeida. Antibiotic-induced dysbiosis effects on the murine gastrointestinal tract and their systemic repercussions. Life Sciences 2018; 207: 480 doi: 10.1016/j.lfs.2018.06.030
|
| 11 |
Edford Sinkala, Michael Vinikoor, Kanekwa Zyambo, Ellen Besa, Bright Nsokolo, Paul Kelly. Propranolol Reduces Portal Vein Diameter in Schistosomal Liver Disease with Portal Hypertension: A Prospective Cohort Study.
The American Journal of Tropical Medicine and Hygiene 2020; 102(4): 832 doi: 10.4269/ajtmh.19-0452
|
| 12 |
Francesca Romana Ponziani, Venanzio Valenza, Erida Nure, Giuseppe Bianco, Giuseppe Marrone, Antonio Grieco, Maurizio Pompili, Antonio Gasbarrini, Salvatore Agnes, Gabriele Sganga, Gianfranco D. Alpini. Effect of liver transplantation on intestinal permeability and correlation with infection episodes. PLOS ONE 2020; 15(6): e0235359 doi: 10.1371/journal.pone.0235359
|
| 13 |
Francesco Santopaolo, Gaetano Coppola, Lucia Giuli, Antonio Gasbarrini, Francesca Romana Ponziani. Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management. Microbiology Research 2022; 13(3): 539 doi: 10.3390/microbiolres13030038
|
| 14 |
Kazuhiko Ikeuchi, Takeya Tsutsumi, Aya Ishizaka, Taketoshi Mizutani, Ayako Sedohara, Michiko Koga, Satoru Tamaoki, Hiroshi Yotsuyanagi. Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis. Gut Pathogens 2023; 15(1) doi: 10.1186/s13099-023-00541-4
|
| 15 |
Daniela Campion, Ilaria Giovo, Paola Ponzo, Giorgio M Saracco, Federico Balzola, Carlo Alessandria. Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis. World Journal of Hepatology 2019; 11(6): 489-512 doi: 10.4254/wjh.v11.i6.489
|
| 16 |
Beatrice Campanella, Massimo Onor, Tommaso Lomonaco, Edoardo Benedetti, Emilia Bramanti. HS-SPME-GC-MS approach for the analysis of volatile salivary metabolites and application in a case study for the indirect assessment of gut microbiota. Analytical and Bioanalytical Chemistry 2019; 411(28): 7551 doi: 10.1007/s00216-019-02158-6
|
| 17 |
Kashif Mohd Siddiqui, Sumeet Attri, Massimo Orlando, Filippo Lelli, Valeria Maida, Dominique Damais-Thabut, Soe Thiha Maung. Cost-Effectiveness of Rifaximin-α versus Lactulose for the Treatment of Recurrent Episodes of Overt Hepatic Encephalopathy: A Meta-Analysis. GastroHep 2022; 2022: 1 doi: 10.1155/2022/1298703
|
| 18 |
Jianwei Chen, Yaojia Lu, Yujie Du, Hong Wang, Qiang Wu. Recent development of small-molecular inhibitors against Clostridioides difficile infection. Bioorganic Chemistry 2022; 125: 105843 doi: 10.1016/j.bioorg.2022.105843
|
| 19 |
Valeria Maccauro, Carlo Airola, Francesco Santopaolo, Antonio Gasbarrini, Francesca Romana Ponziani, Maurizio Pompili. Gut Microbiota and Infectious Complications in Advanced Chronic Liver Disease: Focus on Spontaneous Bacterial Peritonitis. Life 2023; 13(4): 991 doi: 10.3390/life13040991
|
| 20 |
Francesca Romana Ponziani, Alberto Nicoletti, Antonio Gasbarrini, Maurizio Pompili. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919848184
|
| 21 |
Aleksandra Sędzikowska, Leszek Szablewski. Human Gut Microbiota in Health and Selected Cancers. International Journal of Molecular Sciences 2021; 22(24): 13440 doi: 10.3390/ijms222413440
|
| 22 |
V. A. Savarina, V. M. Mitsura. THE ROLE OF THE GUT-LIVER AXIS IN LIVER CIRRHOSIS PATHOGENESIS AND COMPLICATIONS. Hepatology and Gastroenterology 2020; 4(2): 151 doi: 10.25298/2616-5546-2020-4-2-151-154
|
| 23 |
El-Sayed Ibrahim, Ayman Alsebaey, Hassan Zaghla, Sabry Moawad Abdelmageed, Khalid Gameel, Eman Abdelsameea. Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1247 doi: 10.1097/MEG.0000000000000967
|
| 24 |
Yujing Fan, Yunpeng Li, Yanjie Chu, Jing Liu, Lin Cui, Dekai Zhang. Toll-Like Receptors Recognize Intestinal Microbes in Liver Cirrhosis. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.608498
|
| 25 |
Alec B. Rezigh, Erin Armenia, Ting Li, Irene Soesilo. Rifaximin as a rare cause of rhabdomyolysis in cirrhosis. Clinical Case Reports 2018; 6(7): 1296 doi: 10.1002/ccr3.1583
|
| 26 |
Xin-Yue Lv, Hui-Guo Ding, Jun-Fu Zheng, Chun-Lei Fan, Lei Li. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. World Journal of Gastroenterology 2020; 26(2): 199-218 doi: 10.3748/wjg.v26.i2.199
|
| 27 |
Ying Yuan, Xiaomei Wang, Xiangyi Xu, Yu Liu, Cancan Li, Meng Yang, Yiqing Yang, Zhenkun Ma. Evaluation of a Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and Potential Application in the Treatment of Gastrointestinal and Liver Disorders. ACS Infectious Diseases 2020; 6(5): 820 doi: 10.1021/acsinfecdis.9b00374
|
| 28 |
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut and Liver 2017; 11(5): 702 doi: 10.5009/gnl16478
|
| 29 |
Russell Rosenblatt, Amit Mehta, Shirley Cohen‐Mekelburg, Nicole Shen, David Snell, Catherine Lucero, Arun Jesudian, Brett Fortune, Carl V. Crawford, Sonal Kumar. The rise of Clostridioides difficile infections and fall of associated mortality in hospitalized advanced cirrhotics. Liver International 2019; 39(7): 1263 doi: 10.1111/liv.14077
|
| 30 |
Xiaoyuan Xu, Zhongping Duan, Huiguo Ding, Wengang Li, Jidong Jia, Lai Wei, Enqiang Linghu, Hui Zhuang. Chinese guidelines on the management of ascites and its related complications in cirrhosis. Hepatology International 2019; 13(1): 1 doi: 10.1007/s12072-018-09923-2
|
| 31 |
Simona Iacob, Diana Gabriela Iacob. Infectious Threats, the Intestinal Barrier, and Its Trojan Horse: Dysbiosis. Frontiers in Microbiology 2019; 10 doi: 10.3389/fmicb.2019.01676
|
| 32 |
Yao-Guang Li, Zu-Jiang Yu, Ang Li, Zhi-Gang Ren. Gut microbiota alteration and modulation in hepatitis B virus-related fibrosis and complications: Molecular mechanisms and therapeutic inventions. World Journal of Gastroenterology 2022; 28(28): 3555-3572 doi: 10.3748/wjg.v28.i28.3555
|
| 33 |
Mei Luo, Peiwei Xie, Xuehong Deng, Jiahui Fan, Lishou Xiong. Rifaximin Ameliorates Loperamide-Induced Constipation in Rats through the Regulation of Gut Microbiota and Serum Metabolites. Nutrients 2023; 15(21): 4502 doi: 10.3390/nu15214502
|
| 34 |
Xiaoqiang Qi, Ming Yang, Joseph Stenberg, Rahul Dey, Leslie Fogwe, Muhammad Shawkat Alam, Eric T Kimchi, Kevin F Staveley-O'Carroll, Guangfu Li. Gut microbiota mediated molecular events and therapy in liver diseases. World Journal of Gastroenterology 2020; 26(48): 7603-7618 doi: 10.3748/wjg.v26.i48.7603
|
| 35 |
Ji Won Han, Da In Kim, Hee Chul Nam, U Im Chang, Jin Mo Yang, Do Seon Song. Association between serum tumor necrosis factor-α and sarcopenia in liver cirrhosis. Clinical and Molecular Hepatology 2022; 28(2): 219 doi: 10.3350/cmh.2021.0082
|
| 36 |
Y.‐L. Wang, H.‐J. He, X.‐X. Xiao, Y. Lin, B.‐Q. Wang, S.‐L. Zhu, G.‐S. Yang, S.‐S. Huang, Q.‐G. Yang. Letter: rifaximin is more than helping hepatic encephalopathy—it also saves lives. Alimentary Pharmacology & Therapeutics 2017; 46(11-12): 1122 doi: 10.1111/apt.14353
|
| 37 |
Valentina Kebede, Teresa Ravizza, Silvia Balosso, Rossella Di Sapia, Luca Canali, Sara Soldi, Serena Galletti, Christina Papazlatani, Panagiotis A. Karas, Sotirios Vasileiadis, Annalisa Sforzini, Laura Pasetto, Valentina Bonetto, Annamaria Vezzani, Loredana Vesci. Early treatment with rifaximin during epileptogenesis reverses gut alterations and reduces seizure duration in a mouse model of acquired epilepsy. Brain, Behavior, and Immunity 2024; 119: 363 doi: 10.1016/j.bbi.2024.04.007
|
| 38 |
Eric G Meissner. The Gut-Liver Axis in Hepatitis C Virus Infection: A Path Towards Altering the Natural History of Fibrosis Progression?. Clinical Infectious Diseases 2018; 67(6): 878 doi: 10.1093/cid/ciy208
|
| 39 |
Alberto Nicoletti, Francesca Romana Ponziani, Marco Biolato, Venanzio Valenza, Giuseppe Marrone, Gabriele Sganga, Antonio Gasbarrini, Luca Miele, Antonio Grieco. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. World Journal of Gastroenterology 2019; 25(33): 4814-4834 doi: 10.3748/wjg.v25.i33.4814
|
| 40 |
Haonan Li, Yujiao Xiang, Zemeng Zhu, Wei Wang, Zhijun Jiang, Mingyue Zhao, Shuyue Cheng, Fang Pan, Dexiang Liu, Roger C. M. Ho, Cyrus S. H. Ho. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. Journal of Neuroinflammation 2021; 18(1) doi: 10.1186/s12974-021-02303-y
|
| 41 |
Mattia Paratore, Francesco Santopaolo, Giovanni Cammarota, Maurizio Pompili, Antonio Gasbarrini, Francesca Romana Ponziani. Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. Journal of Clinical Medicine 2021; 10(12): 2605 doi: 10.3390/jcm10122605
|
| 42 |
Carlo Airola, Andrea Severino, Serena Porcari, William Fusco, Benjamin H. Mullish, Antonio Gasbarrini, Giovanni Cammarota, Francesca Romana Ponziani, Gianluca Ianiro. Future Modulation of Gut Microbiota: From Eubiotics to FMT, Engineered Bacteria, and Phage Therapy. Antibiotics 2023; 12(5): 868 doi: 10.3390/antibiotics12050868
|
| 43 |
S. Mouri, C. Bouzbib, H. El Mourabit, A. Schaefer, F. Imbert-Bismut, D. Galanaud, S. Tripon, M. Mallet, M. Rudler, C. Housset, D. Thabut, N. Weiss. L’encéphalopathie hépatique, du diagnostic au traitement en 2016. Réanimation 2016; doi: 10.1007/s13546-016-1223-2
|
| 44 |
Francesca Romana Ponziani, Maria Assunta Zocco, Lucia Cerrito, Antonio Gasbarrini, Maurizio Pompili. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Review of Gastroenterology & Hepatology 2018; 12(7): 641 doi: 10.1080/17474124.2018.1481747
|
| 45 |
Tian Qin, Jingyuan Fu, Henkjan J. Verkade. The role of the gut microbiome in graft fibrosis after pediatric liver transplantation. Human Genetics 2021; 140(5): 709 doi: 10.1007/s00439-020-02221-8
|
| 46 |
Pierre Deltenre, Christian Labenz, Marcus Schuchmann. Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α. European Journal of Gastroenterology & Hepatology 2021; 33(1S): e1032 doi: 10.1097/MEG.0000000000002273
|
| 47 |
Mai Abdel Moneim, Doaa H. Abdelaziz, Yosra Ibrahim Nagy, Amin Abdel Baki, Ahmed S. Attia, Nirmeen Sabry. Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus‐related cirrhosis. International Journal of Clinical Practice 2021; 75(11) doi: 10.1111/ijcp.14807
|
| 48 |
Loris R. Lopetuso, Marco Napoli, Gianenrico Rizzatti, Antonio Gasbarrini. The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018; 27(6): 543 doi: 10.1080/13543784.2018.1483333
|
| 49 |
Kazuyuki Suzuki, Ryujin Endo, Yasuhiro Takikawa, Fuminori Moriyasu, Yutaka Aoyagi, Hisataka Moriwaki, Shuji Terai, Isao Sakaida, Yoshiyuki Sakai, Shuhei Nishiguchi, Toru Ishikawa, Hitoshi Takagi, Atsushi Naganuma, Takuya Genda, Takafumi Ichida, Koichi Takaguchi, Katsuhiko Miyazawa, Kiwamu Okita. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a phase III, multicenter, open trial. Hepatology Research 2018; 48(6): 411 doi: 10.1111/hepr.13045
|
| 50 |
Lucia Giuli, Marta Maestri, Francesco Santopaolo, Maurizio Pompili, Francesca Romana Ponziani. Gut Microbiota and Neuroinflammation in Acute Liver Failure and Chronic Liver Disease. Metabolites 2023; 13(6): 772 doi: 10.3390/metabo13060772
|
| 51 |
Lianjun Yang, Bin Liu, Junchi Zheng, Jincheng Huang, Qinghao Zhao, Jinshi Liu, Zhihai Su, Min Wang, Zhifei Cui, Tingxuan Wang, Weicong Zhang, Qingchu Li, Hai Lu. Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice. Frontiers in Cellular and Infection Microbiology 2019; 9 doi: 10.3389/fcimb.2019.00044
|
| 52 |
Beatrice Campanella, Tommaso Lomonaco, Edoardo Benedetti, Massimo Onor, Riccardo Nieri, Emilia Bramanti. Validation and Application of a Derivatization-Free RP-HPLC-DAD Method for the Determination of Low Molecular Weight Salivary Metabolites. International Journal of Environmental Research and Public Health 2020; 17(17): 6158 doi: 10.3390/ijerph17176158
|
| 53 |
Emmanuelle Flatt, Valérie A. McLin, Olivier Braissant, Katarzyna Pierzchala, Paola Mastromarino, Stefanita-Octavian Mitrea, Dario Sessa, Rolf Gruetter, Cristina Cudalbu. Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE. Scientific Reports 2021; 11(1) doi: 10.1038/s41598-021-97018-8
|
| 54 |
皓月 田. The Application of Rifaximin in Patients with End Stage Liver Disease. Advances in Clinical Medicine 2024; 14(01): 466 doi: 10.12677/ACM.2024.141067
|
| 55 |
Sara Montagnese, Francesco Paolo Russo, Piero Amodio, Patrizia Burra, Antonio Gasbarrini, Carmela Loguercio, Giulio Marchesini, Manuela Merli, Francesca Romana Ponziani, Oliviero Riggio, Carmelo Scarpignato. Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2019; 51(2): 190 doi: 10.1016/j.dld.2018.11.035
|